Phase 1/II, Safety and Immunogenicity Study of AERAS-404 in BCG-Primed Infants - Full Text View

Purpose

Phase I/II, randomized, double-blind, placebo-controlled, safety, immunogenicity and dose-range finding study of AERAS-404 Tuberculosis (TB) vaccine administered intramuscularly in Bacille Calmette-Guerin (BCG) primed infants.

Condition	Intervention	Phase
Tuberculosis	Biological: AERAS-404 Biological: Placebo	Phase 1 Phase 2


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Prevention
Official Title:	Phase 1/II, Safety and Immunogenicity Study of a Recombinant Protein Tuberculosis Vaccine (AERAS-404) in BCG-Primed Infants

Resource links provided by NLM:

MedlinePlus related topics: HIV/AIDS Tuberculosis

Genetic and Rare Diseases Information Center resources: Tuberculosis

U.S. FDA Resources

Further study details as provided by Aeras:

Primary Outcome Measures:

Investigate the safety of AERAS-404 in HIV-uninfected, HIV-unexposed, BCG-primed infants. [ Time Frame: Subjects will be followed for up to 1 year and 4 months. ]
Adverse Events and Serious Adverse Events (SAE) will be collected on subjects throughout their participation in the study. Solicited adverse events are captured 28 days post each vaccination. Evaluation of the safety profile of AERAS-404 will be performed using data from all subjects who received at least one dose and has 7 days of safety data, and will be summarized by cohort and treatment group. The number (percentage) of subjects with any adverse event (including solicited, unsolicited, and serious adverse events) will be summarized by Medical Dictionary for Regulatory Activities (MedDRA) system organ class and Preferred Term. Additional summaries will present the number (percentage) of subjects with any adverse events by severity and by relationship to study vaccine; parameters evaluable by the Aeras 404 Pediatric Toxicity Table provided in the protocol, will be summarized by severity corresponding to Toxicity Grade, as appropriate.

Secondary Outcome Measures:

Investigate the safety of a 3-dose AERAS-404 regimen in HIV-uninfected, HIV-unexposed, BCG-primed infants [ Time Frame: Subjects will be followed for up to 1 year and 4 months. ]
The number and percentage of subjects who are enrolled into the three-dose regimen (Cohorts 4-6) with solicited and unsolicited AEs (including serious adverse events [SAEs], local and systemic reactions, and clinical laboratory values or vital sign values recorded as newly abnormal following study vaccination) recorded post-vaccination will be summarized to address the secondary safety objective of the study. Subjects in Cohorts 4 and 5 will be followed for : 1 year and 3 months, Cohort 6: 1 year 4 months and Solicited adverse events are captured 28 days post each vaccination.

Other Outcome Measures:

Assess the immunogenicity of a 3-dose AERAS-404 regimen in HIV-uninfected, HIV-unexposed, BCG-primed infants. [ Time Frame: Subjects will be followed for up to 1 year and 4 months. ]
T-cell response, as measured by Intracellular Cytokine Staining (ICS) following stimulation with peptide pools spanning the vaccine antigens, will be used to assess immunogenicity.
Select an appropriate dose regimen for AERAS-404 in HIV-uninfected, HIV-unexposed, BCG-primed infants. [ Time Frame: After all subjects in Cohorts 4 and 5 have completed Study Day 126, the safety and immunogenicity data from these Cohorts will be evaluated. The data will inform the decision on the study vaccine dose for Cohort 6. ]
Safety and immunogenicity analyses will be reviewed for the selection of the appropriate dose regimen
Explore interactions between AERAS-404 and EPI vaccines. [ Time Frame: Antibody concentration blood samples taken when subjects reach 12 months of age for all Cohorts and in addition, 28 post second study vaccine dose (Study Day 56) for subjects in Cohort 6 only. ]
Antibody concentration levels at 12 months of age for all Cohorts, and in addition at 28 days post second study vaccine dose (Study Day 56) for Cohort 6 will be presented. Summaries will include antibody titers to Tetanus toxoid vaccine (tetanus; given at 6, 10, 14 weeks of age), and Haemophilus influenza B conjugate vaccine (given at 6, 10, 14 weeks of age). Responses to other EPI vaccines may also be assessed.
Assess the immunogenicity of a 2-dose AERAS-404 regimen in HIV-uninfected, HIV-unexposed, BCG-primed infants. [ Time Frame: Subjects will have Immunology samples taken at multiple time points for up to 1 year and 4 months. ]


Enrollment:	243
Actual Study Start Date:	July 1, 2013
Estimated Study Completion Date:	February 2018
Estimated Primary Completion Date:	December 2017 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Cohort 1 Aeras404 (5ug H4/100nmol IC31) or Placebo 1 Dose; Subject ≥ 168 to ≤ 196 days of age	Biological: AERAS-404 AERAS-404 has two components: the H4 antigen and the IC31 adjuvant. The reconstitution of the vaccine components, H4 antigen (manufactured at SP) and IC31 adjuvant (supplied by SSI), will take place at the clinical research site (CRS) prior to injection. Other Name: H4 Biological: Placebo Tris buffered saline (10mM Tris, pH 7.4, 150nm sodium chloride). Other Name: Tris buffered saline
Experimental: Cohort 2 AERAS-404 (5ug H4/500nmol IC31) or Placebo 1 Dose; Subject ≥ 168 to ≤ 196 days of age	Biological: AERAS-404 AERAS-404 has two components: the H4 antigen and the IC31 adjuvant. The reconstitution of the vaccine components, H4 antigen (manufactured at SP) and IC31 adjuvant (supplied by SSI), will take place at the clinical research site (CRS) prior to injection. Other Name: H4 Biological: Placebo Tris buffered saline (10mM Tris, pH 7.4, 150nm sodium chloride). Other Name: Tris buffered saline
Experimental: Cohort 3A AERAS-404 (5ug H4/500nmol IC31) or Placebo 2 Doses; Subject ≥ 168 to ≤ 189 days of age	Biological: AERAS-404 AERAS-404 has two components: the H4 antigen and the IC31 adjuvant. The reconstitution of the vaccine components, H4 antigen (manufactured at SP) and IC31 adjuvant (supplied by SSI), will take place at the clinical research site (CRS) prior to injection. Other Name: H4 Biological: Placebo Tris buffered saline (10mM Tris, pH 7.4, 150nm sodium chloride). Other Name: Tris buffered saline
Experimental: Cohort 3B AERAS-404 (15ug H4/500nmol IC31) or Placebo 2 Doses; Subject ≥ 168 to ≤ 189 days of age	Biological: AERAS-404 AERAS-404 has two components: the H4 antigen and the IC31 adjuvant. The reconstitution of the vaccine components, H4 antigen (manufactured at SP) and IC31 adjuvant (supplied by SSI), will take place at the clinical research site (CRS) prior to injection. Other Name: H4 Biological: Placebo Tris buffered saline (10mM Tris, pH 7.4, 150nm sodium chloride). Other Name: Tris buffered saline
Experimental: Cohort 4 AERAS-404 (15ug H4/500nmol IC31) or Placebo 3 Doses; Subject ≥ 84 to ≤ 98 days of age	Biological: AERAS-404 AERAS-404 has two components: the H4 antigen and the IC31 adjuvant. The reconstitution of the vaccine components, H4 antigen (manufactured at SP) and IC31 adjuvant (supplied by SSI), will take place at the clinical research site (CRS) prior to injection. Other Name: H4 Biological: Placebo Tris buffered saline (10mM Tris, pH 7.4, 150nm sodium chloride). Other Name: Tris buffered saline
Experimental: Cohort 5 AERAS-404 (50ug H4/500nmol IC31) or Placebo 3 Doses; Subject ≥ 84 to ≤ 98 days of age	Biological: AERAS-404 AERAS-404 has two components: the H4 antigen and the IC31 adjuvant. The reconstitution of the vaccine components, H4 antigen (manufactured at SP) and IC31 adjuvant (supplied by SSI), will take place at the clinical research site (CRS) prior to injection. Other Name: H4 Biological: Placebo Tris buffered saline (10mM Tris, pH 7.4, 150nm sodium chloride). Other Name: Tris buffered saline
Experimental: Cohort 6 AERAS-404 (dose level pending) or Placebo 3 Doses; Subject ≥ 64 to ≤ 83 days of age	Biological: AERAS-404 AERAS-404 has two components: the H4 antigen and the IC31 adjuvant. The reconstitution of the vaccine components, H4 antigen (manufactured at SP) and IC31 adjuvant (supplied by SSI), will take place at the clinical research site (CRS) prior to injection. Other Name: H4 Biological: Placebo Tris buffered saline (10mM Tris, pH 7.4, 150nm sodium chloride). Other Name: Tris buffered saline

Detailed Description:

This is a Phase I/II, randomized, double-blind, placebo-controlled, safety, immunogenicity and dose-range finding study in HIV-uninfected, HIV-unexposed, BCG-primed infants. The study vaccine AERAS-404 or placebo will be administered without concomitant EPI vaccines (Cohorts 1 to 5, N = 159 subjects) and with concomitant EPI vaccines (Cohort 6, N = 70 subjects). Study vaccine or placebo will be administered as a single dose (injection) at Study Day 0 ( ≥168 to ≤ 196 days of age, Cohorts 1 and 2), a 2-dose schedule at Study Day 0 (≥ 168 to ≤ 189 days of age) and Study Day 28 (Cohorts 3A and 3B) or a 3-dose schedule at Study Day 0 (≥ 84 to ≤ 98 days of age), Study Day 42 and Study Day 98 (Cohorts 4 and 5). Subjects in Cohort 6 will receive the study vaccine or placebo at Study Day 0 (≥ 64 to ≤ 83 days of age), Study Day 28 (≥ 91 to ≤ 105 days of age), and Study Day 210 (≥ 273 to ≤ 287 days of age). A cohort will enroll once safety in the previous cohort has been established. AERAS-404 is an investigational vaccine manufactured by Sanofi Pasteur (SP) and Statens Serum Institute (SSI).

Eligibility


Ages Eligible for Study:	64 Days to 196 Days (Child)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	Yes

Criteria

INCLUSION CRITERIA

Age at time of entry:

Cohorts 1 to 6
- Cohorts 1 and 2: ≥ 168 to ≤ 196 days
- Cohorts 3A and 3B: ≥ 168 to ≤ 189 days
- Cohorts 4 and 5: ≥ 84 to ≤ 98 days (≥ 2 weeks after receipt of EPI vaccine doses at 10 weeks of age)
- Cohort 6 - coincident with EPI vaccine doses at 10 weeks of age (≥ 64 to ≤ 83 days of age)
Source documentation of birth weight ≥ 2.5 kg.
Documented BCG vaccination within 72 hours of birth.
Documented receipt of all age-appropriate EPI vaccines, except Rotavirus, for Cohorts 4 to 6 (see Appendix II).
Source documentation of a negative HIV status in the mother, from any time during pregnancy with this child through randomization.
Documentation of infant HIV negative exposure or infection status with negative HIV ELISA and HIV DNA PCR tests.
Parent or legal guardian able and willing to provide signed informed consent.
Participant/parent/legal guardian able to attend all scheduled visits and to comply with all trial procedures.

EXCLUSION CRITERIA

History of TB exposure in household or non-household contact.
History/Evidence of TB disease or infection.
Quantiferon positive.
Prior TST test.
Any one of Anemia, Neutropenia, Thrombocytopenia, SGPT (ALT), SGOT (AST) or Creatinine ≥ Grade 2
Receipt of a live vaccine within 28 days prior to randomization.
Receipt or planned receipt of any investigational vaccine.
Known or suspected congenital immunodeficiency.
Receipt of immunosuppressive therapy or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).
Known or suspected autoimmune disease
Hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to a vaccine containing any of the same substances as the vaccine used in the trial.
Participation in another clinical trial for an investigational product (IP).
Bleeding disorder or receipt of anticoagulants in the 3 weeks preceding randomization, contraindicating IM vaccination.
Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion.
Febrile illness (temperature ≥ 100.4°F [≥ 38.0°C]) within 24 hours prior to randomization.

Note: A subject may enroll after recovery from febrile illness if the subject is still within the age window.
Systemic antibiotic use within 48 hours prior to randomization.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01861730

Locations


South Africa
PHRU, Chris Hani Baragwanath Hospital
Johannesburg, Guateng, South Africa, 2091
Shandukani Research
Johannesburg, Hillbrow, South Africa, 2001
KID-CRU, Tygerberg Hospital
Cape Town, Tygerberg, South Africa, 7505
South African TB Vaccine Initiative (SATVI)
Worcester, South Africa

Sponsors and Collaborators

Aeras

Statens Serum Institut

Sanofi Pasteur, a Sanofi Company

National Institute of Allergy and Infectious Diseases (NIAID)

International Maternal Pediatric Adolescent AIDS Clinical Trials Group

Investigators


Study Director:	Zhongkai Shi, MD	Aeras
Principal Investigator:	Avy Violari, MD	Perinatal HIV Research Unit

More Information


Responsible Party:	Aeras
ClinicalTrials.gov Identifier:	NCT01861730 History of Changes
Other Study ID Numbers:	C-015-404/ IMPAACT P1113 U01AI068632 ( U.S. NIH Grant/Contract ) C-015-404 ( Other Identifier: Aeras )
Study First Received:	May 21, 2013
Last Updated:	January 23, 2017

Keywords provided by Aeras:


BCG Vaccinated HIV Negative

Additional relevant MeSH terms:


Tuberculosis Mycobacterium Infections Actinomycetales Infections Gram-Positive Bacterial Infections Bacterial Infections

ClinicalTrials.gov processed this record on September 21, 2017

Phase 1/II, Safety and Immunogenicity Study of AERAS-404 in BCG-Primed Infants (C-015-404)